Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Oct 1 - Oct 6
Concentration (start) Volume (start) = Concentration (final) Volume (final) Purity & Documentation Data Sheet (295 KB) SDS (254 KB) English - EN (254 KB) Franais - FR (254 KB) Deutsch - DE (254 KB) Norwegian - NO (254 KB) Espaol - ES (254 KB) Swedish - SV (254 KB) Italian - IT (254 KB) Korean - KR (254 KB) Portuguese - PT (254 KB) Handling Instructions (2659 KB) References [1]
Solutions: Extend trial to 6 months before concluding inefficacy (some benefits take longer), increase dosing within safe ranges if using lower end, switch peptides (try Cerebrolysin if using BPC-157, or vice versa), add comprehensive eye exam to rule out progression versus peptide failure, consider peptides preventing worsening rather than producing improvement, discontinue if truly no benefit after 6 months rigorous trial
Pathway level effects reported are changes in kinase mediated signal transduction activity, transcriptional activity related to matrix deposition and control of factors associated with cellular migration and adhesion
Important Note on the Evidence Base To our knowledge, no peer-reviewed clinical or preclinical study has tested the specific BPC-157 + TB-500 combination at the amounts or ratios sold in this product
US$ 27.02
US$ 24.85
US$ 20.90
US$ 24.70
US$ 27.18
US$ 22.72
